FOUNTAIN HILLS, Ariz., Aug. 24 /PRNewswire-FirstCall/ -- Sunridge International (OTC Bulletin Board: SNDZ), announced today that it will travel to Europe next month to have meetings with key brokers and funds. The purpose of these meetings will be to bring awareness to our company's technology, and to facilitate funding for Sunridge to execute its business plan for expansion.
"Now is a good time for this project," states G. Richard Smith, CEO of Sunridge. "We have had a presence in Europe through distributors for some time now, and with our recent expansion into India and the Middle East, it makes good sense."
The meeting schedule is being setup by IBIS Consulting LLC, a consulting firm with 10-years of experience pairing companies with European investment funds.
Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International (www.oi-pnt.com).CONTACT:Jeff Smith, Sunridge InternationalT: +1-480-837-6165e-mail: firstname.lastname@example.orgMEDIA:Victor Webb, Marston Webb InternationalT: (212) 684-6601e-mail: email@example.com
|SOURCE Sunridge International|
Copyright©2010 PR Newswire.
All rights reserved